In a groundbreaking legal development, Bayer finds itself grappling with a monumental $332 million Roundup-cancer verdict issued by a San Diego jury. This verdict marks the company’s third loss this month in weedkiller-related cases, and the legal landscape is undergoing significant changes.
To address the mounting challenges, Bayer has allocated a substantial $16 billion for Roundup litigation, underscoring the gravity of the situation. However, the challenges don’t end there. Just last week, a Philadelphia jury delivered a landmark decision, holding Monsanto accountable for $175 million in favor of a cancer patient. The claim was rooted in the failure to provide adequate warnings about the carcinogens present in their widely-used herbicide, Roundup.
These recent events are part of a pattern of major rulings against Bayer AG’s subsidiary. Previous significant verdicts in 2019, like the $2 billion judgment and the $289 million, were reduced on appeal, but their impact is still significant.
The ideal scenario would have involved Bayer resolving all pending cases by 2020 and withdrawing Roundup from the market, thus reducing the risk of future litigation. However, with continued Roundup sales post-settlement, Bayer now faces potential legal challenges.
Presently, there are over 40,000 pending lawsuits related to Roundup, and an estimated additional $7 billion is anticipated to be required to settle these remaining cases. The legal landscape is evolving, and Bayer finds itself at the forefront of a shifting paradigm.
Stay tuned for further updates on this dynamic legal situation as it unfolds.
Do you have a Roundup campaign we can help you with? Schedule a call to discuss your marketing campaign with us. Get qualified retainers today for Roundup! Schedule a Call!
or write to us at [email protected]